The present invention provides novel antigens of an allergy to egg, methods and kits for diagnosing an allergy to egg, pharmaceutical compositions comprising such an antigen, eggs or processed products of egg in which such an antigen is eliminated or reduced, birds that deliver such eggs or are born from such eggs, a method for producing processed products of egg in which such an antigen is eliminated or reduced, and a tester for determining the presence or absence of an egg antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an antigen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and raw materials or processed products in which an antigen comprising such a polypeptide is eliminated or reduced. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

The present invention relates to formulations and methods for preventing food allergies in a subject. Embodiments of the invention provide for administration of allergens from eight types of food that cause food allergies in western societies: peanut, tree nuts, milk, egg, soy, wheat, fish, and shellfish. The allergens may be provided directly to the subject, or to the subject's mother, who may be pregnant or nursing.

The present invention relates to formulations and methods for preventing food allergies in a subject. Embodiments of the invention provide for administration of allergens from eight types of food that cause food allergies in western societies: peanut, tree nuts, milk, egg, soy, wheat, fish, and shellfish. The allergens may be provided directly to the subject, or to the subject's mother, who may be pregnant or nursing.

The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

A method and kit for the sequential early introduction to an infant of at least nine allergens to decrease the infant's risk for developing allergies. The method and kit includes an initial lower exposure dose of a first allergen to be taken for a day or two, followed by a higher maintenance dose of the first allergen to be taken for a day or more. Additional allergens are added, each first at an initial lower dose for a day or more followed by a higher maintenance dose for a day or more. This patent continues until all nine allergens are being given to an infant at their maintenance doses. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula/mother's milk. Alternatively, the allergens can be included in baby formula, or in other foods such as snack bars, cookies, or gels.

A method and kit for the sequential early introduction to an infant of at least nine allergens to decrease the infant's risk for developing allergies. The method and kit includes an initial lower exposure dose of a first allergen to be taken for a day or two, followed by a higher maintenance dose of the first allergen to be taken for a day or more. Additional allergens are added, each first at an initial lower dose for a day or more followed by a higher maintenance dose for a day or more. This patent continues until all nine allergens are being given to an infant at their maintenance doses. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula/mother's milk. Alternatively, the allergens can be included in baby formula, or in other foods such as snack bars, cookies, or gels.

The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.

The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.

The invention relates to tolerogenic compositions and methods for the preparation, manufacture and therapeutic use thereof.

The invention relates to tolerogenic compositions and methods for the preparation, manufacture and therapeutic use thereof.